论文信息 - Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer - 字舞流文

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

F. Clatot | M. Bubenheim | F. Di Fioré | J. Lequesne | A. Perdrix | C. Lévy | C. Guillemet | D. Sefrioui | M. Fontanilles | C. Calbrix | L. Beaussire | C. Alexandru | G. Emile | N. Sarafan‐Vasseur | Lucie Burel | L. Augusto | Sigrid Lacaille | S. Guénot | Doriane Richard | N. Sarafan-vasseur